Our perspectives
in one place
Topic
Selected filters
Clear
News
See allSixth resumed meeting of the open-ended Intergovernmental Working Group (IGWG 6) on the WHO Pandemic Agreement: PABS instrument
On 30 April 2026, IFPMA delivered a statement at the Sixth resumed meeting of the open-ended Intergovernmental Working Group (IGWG 6) on the WHO Pandemic Agreement.
Read moreWTO 14th Ministerial Conference: An opportunity to address trade, innovation, and health
As WTO Members gather in Yaoundé for the 14th Ministerial Conference (MC14), the meeting comes at a pivotal moment for global trade and health.
Read moreSixth meeting of the open-ended Intergovernmental Working Group (IGWG 6) on the WHO Pandemic Agreement: PABS instrument
On 23 March 2026, IFPMA delivered a statement at the Sixth meeting of the open-ended Intergovernmental Working Group (IGWG 6) on the WHO Pandemic Agreement.
Read moreEnsuring harmonized approaches to life cycle assessment of health products
The global innovative pharmaceutical industry recognizes the increasing interest from health systems, procurers, and policymakers in understanding the environmental footprint of medicines and vaccines. As conversations evolve around product-level life cycle assessment (LCA), it is vital that any emerging frameworks support clarity, methodological consistency, and insights that enable companies to improve their own environmental performance....
Read moreStatement at the fifth meeting of the open-ended Intergovernmental Working Group (IGWG 5) on the WHO Pandemic Agreement
On 9 February 2026 in Geneva, IFPMA delivered a statement at the fifth meeting of the open-ended Intergovernmental Working Group (IGWG 5) on the WHO Pandemic Agreement.
Read more158th session of the WHO Executive Board (EB158): Reform of the global health architecture and the UN80 initiative
On 6 February 2026, IFPMA delivered a statement on Agenda item 29.1 on reform of the global health architecture at the 158th session of the WHO Executive Board in Geneva. The innovative pharmaceutical industry views this process as a critical opportunity to build a stronger, truly fit-for-purpose global health architecture. As a trusted and official...
Read morePublications
See allAdvancing GMP inspection reliance – from pilots to practice
Around the world, National Regulatory Agencies (NRAs) face mounting pressure to ensure access to and availability of high-quality medicinal products while confronted with an increasing number of sites to inspect, a demand driven by a need to strengthen supply resilience and manage limited inspection resources. This position paper represents the views of the research-based biopharmaceutical...
Read more
Health security for a safer future
This issue brief by Foreign Policy Analytics (FPA), produced with support from IFPMA, examines global health security, highlighting international coordination to strengthen preparedness is vital to protecting lives, economies, and societies from the next major health crisis.
Read more
Strengthening global health security: Perspectives from the innovative pharmaceutical industry
IFPMA publication “Strengthening global health security: Perspectives from the innovative pharmaceutical industry”presents the pharmaceutical industry as a central partner in global health security, and capturing the sector’s contributions, key challenges, and concrete policy recommendations.
Read more
Expert insights
See all
Foundations of competitiveness and growth start with strong healthcare systems and healthy populations
Read more
A better global health architecture delivers both innovation and access
Read more
A new dawn in global health: UHC as the path toward national health stewardship
Read moreResources
See allStreamlining samples management to strengthen health outcomes in Africa
Ensuring the quality, safety, and efficacy of pharmaceutical products is a cornerstone of public health. To meet these high standards, innovative multinational pharmaceutical companies perform rigorous batch release testing for every product, following internationally recognized protocols and approved specifications. However, countries may require additional in-country testing by their National Regulatory Authorities (NRAs) or National Control...
Read more
Our Ethos in Action – Decision-Making Framework Toolkit
IFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read more
February 2024: Impact of a waiver of intellectual property rights for COVID-19 therapeutics
As discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.
Read more